IQV · IQVIA Holdings, Inc.
$260.45
+1.22% last session
End-of-day data · close of 2026-09-11
Market cap
$42B
Enterprise value
$57B
Trailing P/E
32.0
Forward P/E
17.8
Dividend yield
—
Beta
1.19
Avg volume
1M
Employees
94K
Daily Change %
1.22%
5 Days Change
-4.03%
10 Days Change
-1.61%
30 Days Change
5.39%
60 Days Change
23.64%
Month to Day Change
-0.53%
Year to Day Change
14.01%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IQV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-29
Latest call per bank · past 12 months
JP Morgan
Overweight$285
+10.8% vs priceRBC Capital
Outperform$247
-4.0% vs priceMorgan Stanley
Equal-Weight$200
-22.3% vs priceBarclays
Overweight$210
-18.4% vs priceCitigroup
Neutral$200
-22.3% vs priceUBS
Buy$240
-6.7% vs priceJefferies
Buy$255
-0.9% vs priceHSBC
Buy$235
-8.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-29 | JP Morgan | Maintains | Overweight | $225 → $285 |
| 2026-07-29 | Stifel | Maintains | Buy | $220 → $276 |
| 2026-07-29 | TD Cowen | Maintains | Buy | $233 → $288 |
| 2026-07-29 | RBC Capital | Maintains | Outperform | $221 → $247 |
| 2026-07-29 | BMO Capital | Maintains | Outperform | $210 → $270 |
| 2026-07-29 | Baird | Maintains | Outperform | $252 → $287 |
| 2026-07-13 | Mizuho | Maintains | Outperform | $215 → $230 |
| 2026-07-01 | Baird | Maintains | Outperform | $230 → $249 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 10.7% above the 50-day MA ($235.19).
- Price vs 200-day MA: Trading 28.5% above the 200-day MA ($202.67).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.91) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($271.62).
IQV Price Chart
Loading chart for IQV…
Fundamentals
About IQVIA Holdings, Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$223B 4.7% YTD
DHR
Danaher Corporation
$141B -10.1% YTD
NTRA
Natera, Inc.
$47B 44.2% YTD
IDXX
IDEXX Laboratories, Inc.
$40B -23.8% YTD
A
Agilent Technologies, Inc.
$40B 7.0% YTD
WAT
Waters Corporation
$39B 6.6% YTD
ILMN
Illumina, Inc.
$30B 56.3% YTD
MTD
Mettler-Toledo International, I
$26B -7.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.